Skip to main content

Table 2 Changes of areal bone mineral density, mobility, and height between start of trial, end of the trial and end of follow up period

From: Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort

  Number of patients Start of trial End of trial End of follow up p-value Start and end of trial p-value End of trial and end of follow up p-value End of follow up – End of trial Vs End of trial- Start of trial
aBMD lumbar vertebrae L2-L4 (g/cm2) (mean ± SD) 8 0.533 ± 0.202 0.634 ± 0.251 0.5676 ± 0.221 0.0041 0.028 0.0067
aBMD lumbar vertebrae L2-L4 z-score (mean ± SD) 8 −1.975 ± 2.217 − 1.013 ± 2.606 −1.913 ± 2.121 0.0037 0.015 0.0051
aBMD total body without head (g/cm2) (mean ± SD) 8 0.514 ± 0.116 0.587 ± 0.138 0.561 ± 0.129 0.0002 0.123 0.0035
aBMD total body without head z-score (mean ± SD) 8 −1.925 ± 1.624 −1.313 ± 1.755 −2.088 ± 1.54 0.0046 0.005 0.0036
Spine score (points) (mean ± SD) 9 24.33 ± 32.8 23.78 ± 34.64 20.33 ± 28.47 0.766 0.532 0.6415
GMFM 88 (%) (mean ± SD) 9 76.33 ± 33.58 78.83 ± 32.86 72.34 ± 34.75 0.198 0.077 0.0522
Height [cm] (mean ± SD) 9 106.4 ± 21 110.1 ± 22.7 115.5 ± 24.2 0.0004 0.0001 0.024
Height z-Scores (mean ± SD) 9 −4.467 ± 4.22 −4.533 ± 4.36 − 4.344 ± 4.61 0.6606 0.332 0.027